Treatment with systemic cyclophosphamide or systemic ifosfamide

Malignant neoplasm of the bladder - Treatment with systemic cyclophosphamide or systemic ifosfamide Factor

Ifosfamide is a chemotherapeutic agent used alone or in combination with other agents to treat tumours such as germ cell tumours, sarcomas and lymphomas, ovarian and cervical cancers, and lung and breast cancers.  The drug is given as an infusion under the brand name Holoxan.

Systemic means "affecting the entire body," rather than a single organ or body part.

fosfamide

Ifosfamide is a chemotherapeutic agent used alone or in combination with other agents to treat tumours such as germ cell tumours, sarcomas and lymphomas, ovarian and cervical cancers, and lung and breast cancers.  The drug is given as an infusion under the brand name Holoxan.

Systemic means "affecting the entire body," rather than a single organ or body part.

PRELIMINARY QUESTIONS [11713]

11757 there is some evidence that treatment with systemic cyclophosphamide or systemic ifosfamide may be a factor in the development of the condition under consideration.

11758 the veteran has been treated with systemic cyclophosphamide or systemic ifosfamide at some time.

11760 the veteran was treated with systemic cyclophosphamide or systemic ifosfamide at least 5 years before the clinical onset of the condition under consideration.

11759  the veteran was treated with systemic cyclophosphamide or systemic ifosfamide at least 5 years before the clinical onset of the condition under consideration for treatment of an illness or injury which is identifiable. [Default true]

11761  the veteran has established the causal connection between the treatment with systemic cyclophosphamide or systemic ifosfamide and VEA service for the clinical onset of malignant neoplasm of the bladder.

11762   the veteran has established the causal connection between the treatment with systemic cyclophosphamide or systemic ifosfamide and operational service for the clinical onset of malignant neoplasm of the bladder.

or

11763   the veteran has established the causal connection between the treatment with systemic cyclophosphamide or systemic ifosfamide and eligible service for the clinical onset of malignant neoplasm of the bladder.

CLINICAL ONSET AND OPERATIONAL SERVICE [11762]

11764  the identified illness or injury, for which treatment with systemic cyclophosphamide or systemic ifosfamide was given, is causally related to operational service.

CLINICAL ONSET AND ELIGIBLE SERVICE [11763]

11765  the identified illness or injury, for which treatment with systemic cyclophosphamide or systemic ifosfamide was given, is causally related to eligible service.